Polymorphisms in chemokine and receptor genes and gastric cancer risk and survival in a high risk Polish population

Abstract

Objective. To examine if genetic variations in chemokine receptor and ligand genes are associated with gastric cancer risk and survival. Methods. The study included 298 cases and 417 controls from a population-based study of gastric cancer conducted in Warsaw, Poland in 1994–1996. We investigated seven single nucleotide polymorphisms in a chemokine ligand (CXCL12) and chemokine receptor (CCR2, CCR5, CX3CR1) genes and one frameshift deletion (CCR5) in blood leukocyte DNA in relation to gastric cancer risk and survival. Genotyping was conducted at the NCI Core Genotyping Facility. Odds ratios and 95% confidence intervals were computed using univariate and multivariate logistic regression models. Survival analysis was performed using Cox proportional hazards models. Results. Gastric cancer risk was not associated with single chemokine polymorphisms. A CCR5 haplotype that contained the common alleles of IVS1+151 G>T (rs2734648), IVS2+80 C>T (rs1800024) and minor allele of IVS1+246 A>G (rs1799987) was associated with a borderline significantly increased risk (OR = 1.5, 95% CI: 1.0–2.2). For gastric cancer cases, there was a greater risk of death for carriers of the minor alleles of CCR2 Ex2+241 G>A (rs1799864) (HR = 1.5, 95% CI: 1.1–2.1) and CCR5 IVS2+80 C>T (rs1800024) (HR = 1.5, 95% CI: 1.1–2.1). Carriers of the CCR5 minor allele of IVS1+151 G>T (rs2734648) had a decreased risk of death compared to homozygote carriers of the common allele (HR = 0.8, 95% CI: 0.6–1.0). Conclusions. Our findings do not support an association between gastric cancer risk and single chemokine genetic variation. The observed associations between cancer risk and a CCR5 haplotype and between survival and polymorphisms in CCR2 and CCR5 need replication in future studies.

Key Words::

• Chemokine
• gastric cancer
• single nucleotide polymorphisms
• survival

Acknowledgements

This study was supported, in part, by the Intramural Research Program, Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH. Salary support (AJG) was provided by the Physician Scientist Training Program of the Feinberg School of Medicine, Northwestern University. We would also like to thank Jason Sinnwell (Mayo Clinic, Rochester, MN) for his assistance with Haplo Stats.

Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.